Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 40 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. The primary objective of this study is to evaluate the safety and tolerability of AT193. The secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of HS.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis Suppurativa
Estimated Study Start Date: October 1, 2021
Estimated Primary Completion Date: June 15, 2022
Estimated Study Completion Date: June 15, 2022
Arms:
- Experimental: AT193
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 40 |
| Estimated Study start date | 01 October 2021 |
| Estimated Study Completion Date | 15 June 2022 |